Magnolia Medical Expands Steripath® Micro Initial Specimen Diversion Device® (ISDD®) Product Family with New FDA 510(k) Clearance

MagnoliaAvery WilliamsApril 11, 20232023

Magnolia Medical: United Hospital Center Improves Patient Outcomes and Margins by Avoiding False-Positive Blood Cultures

MagnoliaAvery WilliamsNovember 14, 20222022

BD, Magnolia Medical Technologies Announce Commercial Collaboration to Help Reduce Blood Culture Contamination and Improve Testing Accuracy

MagnoliaAvery WilliamsOctober 18, 20222022

Magnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc.

MagnoliaAvery WilliamsJuly 29, 20222022

Magnolia Medical Announces $46 Million Growth Equity Financing

MagnoliaAvery WilliamsFebruary 18, 20222022

Magnolia Medical Announces Partnership with Cardinal Health

Magnolia Medical Technologies announced today a collaboration with Cardinal Health focused on improving clinical and economic outcomes by reducing blood culture contamination and false-positive diagnostic results for sepsis.

MagnoliaAvery WilliamsNovember 14, 20192019

HealthQuest leads $13.8M into Magnolia Medical

Magnolia Medical Technologies, developer of the SteriPath® blood collection system and leader in improving the quality and accuracy of in-vitro diagnostic test results, today announced the closing of the company's $13.8 million Series B financing led by HealthQuest Capital. In conjunction with the financing, Garheng Kong, M.D., Ph.D., founder and managing partner of HealthQuest Capital will join the company's board.